Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/C3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/C3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/C3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/C3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/C3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/C3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/C3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/C3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000991321 | Stomach | CSG | epidermal cell differentiation | 21/1034 | 202/18723 | 4.02e-03 | 3.48e-02 | 21 |
GO:00704242 | Stomach | CSG | regulation of nucleotide-binding oligomerization domain containing signaling pathway | 4/1034 | 13/18723 | 4.43e-03 | 3.75e-02 | 4 |
GO:007138321 | Stomach | CSG | cellular response to steroid hormone stimulus | 21/1034 | 204/18723 | 4.51e-03 | 3.81e-02 | 21 |
GO:00485252 | Stomach | CSG | negative regulation of viral process | 12/1034 | 92/18723 | 4.63e-03 | 3.90e-02 | 12 |
GO:00024602 | Stomach | CSG | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/1034 | 356/18723 | 4.71e-03 | 3.95e-02 | 32 |
GO:00193692 | Stomach | CSG | arachidonic acid metabolic process | 9/1034 | 59/18723 | 4.80e-03 | 4.02e-02 | 9 |
GO:19026441 | Stomach | CSG | tertiary alcohol metabolic process | 5/1034 | 21/18723 | 4.93e-03 | 4.08e-02 | 5 |
GO:003166821 | Stomach | CSG | cellular response to extracellular stimulus | 24/1034 | 246/18723 | 4.97e-03 | 4.10e-02 | 24 |
GO:00622071 | Stomach | CSG | regulation of pattern recognition receptor signaling pathway | 13/1034 | 105/18723 | 5.15e-03 | 4.18e-02 | 13 |
GO:000608121 | Stomach | CSG | cellular aldehyde metabolic process | 9/1034 | 60/18723 | 5.38e-03 | 4.33e-02 | 9 |
GO:00069562 | Stomach | CSG | complement activation | 15/1034 | 130/18723 | 5.42e-03 | 4.35e-02 | 15 |
GO:00022531 | Stomach | CSG | activation of immune response | 33/1034 | 375/18723 | 5.70e-03 | 4.54e-02 | 33 |
GO:006201221 | Stomach | CSG | regulation of small molecule metabolic process | 30/1034 | 334/18723 | 6.13e-03 | 4.77e-02 | 30 |
GO:0098586 | Stomach | CSG | cellular response to virus | 11/1034 | 84/18723 | 6.37e-03 | 4.92e-02 | 11 |
GO:0006636 | Stomach | CSG | unsaturated fatty acid biosynthetic process | 8/1034 | 51/18723 | 6.46e-03 | 4.99e-02 | 8 |
GO:005254731 | Stomach | CAG | regulation of peptidase activity | 40/552 | 461/18723 | 1.15e-09 | 2.58e-07 | 40 |
GO:005254831 | Stomach | CAG | regulation of endopeptidase activity | 37/552 | 432/18723 | 7.00e-09 | 9.47e-07 | 37 |
GO:190332031 | Stomach | CAG | regulation of protein modification by small protein conjugation or removal | 24/552 | 242/18723 | 2.30e-07 | 1.90e-05 | 24 |
GO:003139631 | Stomach | CAG | regulation of protein ubiquitination | 22/552 | 210/18723 | 2.84e-07 | 2.30e-05 | 22 |
GO:190290331 | Stomach | CAG | regulation of supramolecular fiber organization | 30/552 | 383/18723 | 1.27e-06 | 8.20e-05 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C3 | SNV | Missense_Mutation | novel | c.2800N>C | p.Glu934Gln | p.E934Q | P01024 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
C3 | SNV | Missense_Mutation | | c.1052C>T | p.Ser351Phe | p.S351F | P01024 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
C3 | SNV | Missense_Mutation | rs199911426 | c.4594N>T | p.Arg1532Trp | p.R1532W | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
C3 | SNV | Missense_Mutation | | c.4276N>A | p.Asp1426Asn | p.D1426N | P01024 | protein_coding | deleterious(0.01) | probably_damaging(0.929) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | | c.3803N>G | p.Ser1268Cys | p.S1268C | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Leu | p.S459L | P01024 | protein_coding | tolerated(0.09) | possibly_damaging(0.599) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | novel | c.4408N>A | p.Glu1470Lys | p.E1470K | P01024 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | novel | c.3118G>C | p.Glu1040Gln | p.E1040Q | P01024 | protein_coding | tolerated(0.11) | benign(0.063) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
C3 | SNV | Missense_Mutation | novel | c.2782N>G | p.Ser928Ala | p.S928A | P01024 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C3 | SNV | Missense_Mutation | | c.1452N>T | p.Glu484Asp | p.E484D | P01024 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | Imprime PGG immunotherapeutic | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | 19025129 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | COMPSTATIN | COMPSTATIN | 25494040 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | APL-2 | PEGCETACOPLAN | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | clozapine | CLOZAPINE | 26503818 |